| Psoriasis vulgaris
Bimzelx vs Ultravate
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Bimzelx vs Ultravate with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltravate has a higher rate of injection site reactions vs Bimzelx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultravate but not Bimzelx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bimzelx
Ultravate
At A Glance
SC injection
Every 4-8 weeks
IL-17A and F antagonist
Topical
Twice daily
Topical corticosteroid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Non-Radiographic Axial Spondyloarthritis
- Ankylosing spondylitis
- Hidradenitis Suppurativa
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.
Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.
Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.
Psoriasis vulgaris Apply a thin layer to affected skin twice daily for up to two weeks; total dosage should not exceed 50 grams (50 ml) per week.
Contraindications
—
—
Adverse Reactions
Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection
Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease
Postmarketing Conjunctivitis, esophageal candidiasis
Most common (>=1%) Telangiectasia, application site atrophy, headache
Less common (<1%, >0.1%) Application site discoloration, herpes zoster, influenza, nasopharyngitis, otitis media acute, throat infection, wound, increased blood pressure
Pharmacology
Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.
Halobetasol propionate is a super-high potency topical corticosteroid that plays a role in cellular signaling, immune function, inflammation, and protein regulation; the precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bimzelx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ultravate
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Bimzelx
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Ultravate
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Bimzelx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ultravate
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
Bimzelx BridgeCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultravate.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BimzelxView full Bimzelx profile
UltravateView full Ultravate profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.